1.	Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107DBR01, NCT00751036
2.	Nilotinib Versus Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107A2405, NCT00760877
3.	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107G2301, NCT00785785
4.	Suboptimal Study Comparing Nilotinib and Imatinib Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107A2404, NCT00802841
5.	Phase II Study of a Non-Myeloablative Conditioning Regimen Comprising Fludarabine and Total Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Imatinib Mesylate, Dasatinib, or Nilotinib-Responsive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Blast Crisis Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: NCI Protocol IDs: FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738
6.	Phase I/II Pilot Study of Imatinib Mesylate and/or Nilotinib After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: FHCRC-2223.00, 6691, FHCRC-IR-6691, NOVARTIS-FHCRC-2223.00, NCT00702403
7.	Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAMN107ADE01, NCT00762632
8.	Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2005-0048, NCT00129740
9.	Nilotinib as First-Line Treatment of Ph+ CML in Early Chronic Phase Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CML0307, NCT00481052
10.	Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107DIL02, NCT00633295
11.	Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107AUS09, NCT00644878
12.	Nilotinib Pre and Post Allogeneic Stem Cell Transplantation Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: SHEBA-08-5288-AN-CTIL, NCT00750659
13.	Phase II Study of Nilotinib and Imatinib Mesylate in Patients With Philadelphia Chromosome- and BCR-ABL-Positive Early Chronic Phase Chronic Myelogenous Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and older Sponsor: Other Protocol IDs: GIMEMA-CML0408, GIMEMA-CML0408, EUDRACT-2008-004384-19, EU-20881, NCT00769327
14.	Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107DDE06, EUDRACT- Nr. 2008-000358-11, NCT00756509
15.	Nilotinib in Advanced GIST Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAMN107DUS05T, NCT00782834
16.	Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-244, DUS11T, NCT00788775
17.	Phase II Study of Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myelogenous Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ICORG-08-02, ICORG 08-02, EUDRACT-2008-004551-30, EU-20899, NCT00809211
18.	Phase II Study of Nilotinib and Combination Chemotherapy in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Acute Mixed Lineage Leukemia Phase: Phase II Type: Treatment Status: Active Age: 15 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: AMC-UUCM-2008-0310, 2008-0310, NOVARTIS-AMC-UUCM-2008-0310, NCT00844298